To that end, we first classified the samples based on the levels of PGC1A between high and low, and found that the number of patients with carcinomas in the high group was higher than in the low group, whereas in the hyperplasia group the distribution in the groups was not statistically significantly different, indicating that the evaluation of PGC1A per se can be functionally significant only in carcinomas. Here, PPARGC1A is linked to carcinoma.